CE
Cell Bio Human Tech Co., Ltd
318160 | KO
Overview
Corporate Details
- ISIN(s):
- KR7318160009
- LEI:
- Country:
- South Korea
- Address:
- 경기도 안양시 동안구 시민대로 401 대륭테크노타운15차 제2001호,제2101호, 안양시
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.8 KB | ||
| 2025-09-19 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 53.0 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 28.2 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 28.2 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
신탁계약해지결과보고서
|
Korean | 20.6 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
신탁계약해지결과보고서
|
Korean | 22.3 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
[기재정정]주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 31.1 KB | ||
| 2025-08-28 00:00 |
Interim / Quarterly Report
[기재정정]반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-08-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-06-02 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2025-05-27 00:00 |
Major Shareholding Notification
신탁계약에의한취득상황보고서
|
Korean | 52.6 KB | ||
| 2025-05-27 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-05-14 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-04-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB |
Automate Your Workflow. Get a real-time feed of all Cell Bio Human Tech Co., Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Cell Bio Human Tech Co., Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cell Bio Human Tech Co., Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
United States of America
GNPX
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland
GX1
Poland
GX1
Developing vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.
United States of America
GOVX
United States of America
GOVX
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS
United States of America
GHRS
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea
358570
South Korea
358570
A cell programming platform offering R&D services for pharma, agriculture, food, and chemicals.
United States of America
DNA
United States of America
DNA
A biotech company that detects multiple cancers early with a single blood test.
United States of America
GRAL
United States of America
GRAL
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America
GTBP
United States of America
GTBP
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden
GUARD
Sweden
GUARD
CRO & biotech accelerating peptide drug discovery for metabolic and fibrotic diseases.
Denmark
GUBRA
Denmark
GUBRA